Allergan PLC. (AGN) Position Cut by Ameritas Investment Partners Inc.
Ameritas Investment Partners Inc. lowered its stake in Allergan PLC. (NYSE:AGN) by 11.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,999 shares of the company’s stock after selling 2,305 shares during the period. Ameritas Investment Partners Inc.’s holdings in Allergan PLC. were worth $4,061,000 as of its most recent filing with the SEC.
Other large investors have also bought and sold shares of the company. Crestwood Advisors Group LLC purchased a new stake in shares of Allergan PLC. during the first quarter worth $103,000. Feltz Wealth PLAN Inc. purchased a new stake in shares of Allergan PLC. during the first quarter worth $107,000. Enterprise Financial Services Corp increased its stake in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after buying an additional 178 shares during the period. Sunbelt Securities Inc. purchased a new stake in shares of Allergan PLC. during the fourth quarter worth $107,000. Finally, Webster Bank N. A. increased its stake in shares of Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock worth $124,000 after buying an additional 123 shares during the period. Institutional investors own 84.63% of the company’s stock.
Allergan PLC. (NYSE AGN) opened at 246.09 on Wednesday. The firm’s 50-day moving average price is $230.38 and its 200-day moving average price is $227.81. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $261.27. The firm has a market cap of $82.65 billion, a price-to-earnings ratio of 7.67 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Tuesday, May 9th. The company reported $3.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.32 by $0.03. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The business had revenue of $3.57 billion during the quarter, compared to analysts’ expectations of $3.53 billion. During the same period in the prior year, the firm posted $3.04 EPS. Allergan PLC.’s quarterly revenue was up 5.1% compared to the same quarter last year. Equities research analysts predict that Allergan PLC. will post $16.08 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, June 15th. Stockholders of record on Thursday, May 18th were issued a $0.70 dividend. The ex-dividend date was Tuesday, May 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.14%. Allergan PLC.’s payout ratio is presently 9.63%.
TRADEMARK VIOLATION NOTICE: “Allergan PLC. (AGN) Position Cut by Ameritas Investment Partners Inc.” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/allergan-plc-agn-position-cut-by-ameritas-investment-partners-inc/1398505.html.
A number of equities research analysts have recently weighed in on AGN shares. Goldman Sachs Group, Inc. (The) downgraded Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target for the company. in a report on Wednesday, May 10th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Royal Bank Of Canada set a $279.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Wednesday, April 12th. Deutsche Bank AG boosted their price target on Allergan PLC. from $262.00 to $265.00 and gave the company a “buy” rating in a report on Tuesday, March 28th. Finally, Citigroup Inc. boosted their price target on Allergan PLC. to $261.00 and gave the company a “buy” rating in a report on Monday, April 24th. Eight equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $271.38.
In other news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.